Cell-surface N-linked terminal galactose–bearing glycoconjugates (None)

Cell-surface N-linked terminal galactose–bearing glycoconjugates are a class of glycoproteins and glycolipids where the N-linked oligosaccharide chains terminate in a galactose residue rather than the typical sialic acid. In healthy tissues, these terminal galactose residues are typically masked by sialylation; however, they become exposed or overexpressed in various pathological conditions, such as cancer, inflammation, and certain infections. These glycoconjugates serve as critical ligands for endogenous lectins, most notably the Galectin family and the Asialoglycoprotein Receptor (ASGPR). In oncology, the binding of Galectin-3 to these terminal galactose residues forms a "Galectin-glycan lattice" that stabilizes growth factor receptors on the cell surface, thereby promoting tumor cell survival, migration, and immune evasion. Furthermore, these structures are the primary targets for potent toxins like Ricin and Abrin, which utilize their lectin domains to bind terminal galactose and enter the cell. Therapeutically, these glycoconjugates are targeted by lectin-based drugs such as Mistletoe lectin and are exploited for liver-targeted drug delivery through the use of galactose or N-acetylgalactosamine (GalNAc) conjugates that bind to the ASGPR. Additionally, the terminal galactose epitope Gal-alpha-1,3-Gal (Alpha-gal) is a major target of pre-existing antibodies in humans, playing a central role in xenograft rejection and alpha-gal syndrome.

Other names

AsialoglycoproteinsGalactose-terminated N-glycansAsialo-N-glycansTerminal galactose-bearing glycoproteinsGalactose-terminated glycoconjugates

Drugs targeting these glycoconjugates typically function as lectins or antibodies that bind to the terminal galactose residues. This binding can trigger cell death (in the case of toxins like Ricin or Mistletoe lectin), facilitate internalization for drug delivery (via ASGPR), or block the interaction with endogenous lectins like Galectins to disrupt the Galectin-glycan lattice and modulate cell signaling.